Dermatology
Page 1 • 3 itemsAccess global dermatology market intelligence, drug development trends, and regulatory insights for pharma BD, investors, and analysts.
MorphoSys' MINJUVI (Tafasitamab) Approved in Australia for Relapsed/Refractory Follicular Lymphoma
Australia approves MINJUVI (tafasitamab) as first chemotherapy-free dual-targeted immunotherapy for relapsed/refractory follicular lymphoma patients.
Dayspring Pharma's CG2001 Foam Meets Primary Endpoint in Phase II Male Pattern Baldness Trial
Dayspring Pharma announces positive Phase II results for CG2001 foam in treating male pattern baldness, showing significant efficacy in Chinese men.
Zai Lab's ZL-1503 Bispecific Antibody Shows Rapid Itch Relief in Atopic Disease Preclinical Data
Zai Lab presents promising preclinical data for ZL-1503, an IL-13/IL-31Rα bispecific antibody targeting rapid itch relief and inflammation reduction in atopic diseases.